Investors and shareholders

Inspiring the enterprise of tomorrow and anticipating its challenges by multiplying synergies.

Ecological and social transition, data security, process fluidity... Today, more than ever, companies are facing numerous challenges and must prove their ability to evolve.


With an offer based on 3 pillars, we assist our customers so that they can grow their long-term potential:


  • Consult: advise and assist our clients from the first day;
  • Engage: integrate the selected solutions of our partners and publish our own software packages and thus provide them with tools adapted to succeed in their digital transformation;
  • Connect: help them to develop their network and to interact with their peers.

Stock market course


Visiativ has been listed on Euronext Growth Paris since 2014 (FR0004029478, ALVIV).

Provisional financial calendar


These dates are given as an indication and may be subject to change if necessary. All publications will be issued after close of trading on Euronext Paris


    Annual results 2021


    Q1 revenue 2022


    General assembly 2022


    6 months revenue 2022


    6 months results 2022


    9 months revenue 2022


    Annual revenue 2022


    Annual results 2022

Financial communications

Download all the latest financial press releases.


  • Le 27/07/2022 à 18h00

    Dynamic business trends in H1 2022

    Visiativ reported a sound first-half performance in 2022, generating consolidated revenue of €110.1m, representing strong growth of +20% compared with H1 2021. Organic growth came to 13%.

    Know more
  • Le 26/07/2022 à 18h00

    Daxium-Air joins the Visiativ dynamic

    Visiativ announces today the acquisition of 68% of the capital of Daxium, editor of the Daxium-Air software platform. This SaaS platform enables easy creation of customisable mobile business applications, adapted to the needs of nomadic teams.

    Download the document
  • Le 19/07/2022 à 18h00

    Development of international consulting activities

    Download the document

Suscribe to ours news